Evidence map›Paper›PMID 35440032›Full record

ArticleBreast cancer research : BCR2022

PTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development.

Diego Y Grinman, Kata Boras-Granic, Farzin M Takyar, Pamela Dann, Julie R Hens, Christina Marmol, Jongwon Lee, Jungmin Choi, Lewis A Chodosh, Martin E Garcia Sola and 1 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 4 countries.

Diego Y Grinman *Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, 300 Cedar Street, TAC S120, Box 208020, New Haven, CT, 06520-8020, USA. diego.grinman@yale.edu.
Kata Boras-Granic *Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, 300 Cedar Street, TAC S120, Box 208020, New Haven, CT, 06520-8020, USA.
Farzin M Takyar *Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pamela DannSection of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, 300 Cedar Street, TAC S120, Box 208020, New Haven, CT, 06520-8020, USA.
Julie R HensSection of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, 300 Cedar Street, TAC S120, Box 208020, New Haven, CT, 06520-8020, USA.
Christina MarmolPrimeCare Health, 3924 W Fullerton Ave, Chicago, IL, 60647, USA.
Jongwon LeeBrain Korea 21 Plus Project for Biomedical Science, Korea University College of Medicine, Seoul, Korea.
Jungmin ChoiDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Lewis A ChodoshDepartment of Cancer Biology, Perlman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Martin E Garcia SolaDepartamento de Fisiología y Biología Molecular y Celular, Instituto de Fisiología, Biología Molecular y Neurociencias (IFIByNE), CONICET, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.
John J WysolmerskiSection of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, 300 Cedar Street, TAC S120, Box 208020, New Haven, CT, 06520-8020, USA.
Yale University · USFundación Ciencias Exactas y Naturales · ARKorea University · KRMemorialCare Health System · USResearch Institute for Endocrine Sciences · IRUniversity of Pennsylvania · US

Funding

In Vivo Ras-induced Senescence and TumorigenesisR01CA098371 · NCI · UNIVERSITY OF PENNSYLVANIA · PI LEWIS A CHODOSH · 2003 to 2026
$7.4M
PMCA2 regulates mammary gland involution and breast cancerR01HD076248 · NICHD · YALE UNIVERSITY · PI WYSOLMERSKI, JOHN J · 2014 to 2024
$4.4M
Survival and Recurrence of Dormant Cancer CellsR01CA148774 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHODOSH, LEWIS A · 2010 to 2022
$3.4M
Heterodimerization of the Calcium-sensing receptor with the GabaB receptors in the breast.R01HD100468 · NICHD · YALE UNIVERSITY · PI WYSOLMERSKI, JOHN J · 2020 to 2024
$2.1M
FUNCTION OF THE CALCIUM SENSING RECEPTOR IN THE BREASTR01DK069542 · NIDDK · YALE UNIVERSITY · PI WYSOLMERSKI, JOHN J · 2005 to 2009
$1.6M
NCI NIH HHS R01 CA098371NCI NIH HHS R01 CA148774NICHD NIH HHS R01 HD076248NICHD NIH HHS R01 HD100468
6 · The paper itself

Abstract

backgroundParathyroid hormone-related protein (PTHrP) is required for embryonic breast development and has important functions during lactation, when it is produced by alveolar epithelial cells and secreted into the maternal circulation to mobilize skeletal calcium used for milk production. PTHrP is also produced by breast cancers, and GWAS studies suggest that it influences breast cancer risk. However, the exact functions of PTHrP in breast cancer biology remain unsettled.

methodsWe developed a tetracycline-regulated, MMTV (mouse mammary tumor virus)-driven model of PTHrP overexpression in mammary epithelial cells (Tet-PTHrP mice) and bred these mice with the MMTV-PyMT (polyoma middle tumor-antigen) breast cancer model to analyze the impact of PTHrP overexpression on normal mammary gland biology and in breast cancer progression.

resultsOverexpression of PTHrP in luminal epithelial cells caused alveolar hyperplasia and secretory differentiation of the mammary epithelium with milk production. This was accompanied by activation of Stat5 and increased expression of E74-like factor-5 (Elf5) as well as a delay in post-lactation involution. In MMTV-PyMT mice, overexpression of PTHrP (Tet-PTHrP;PyMT mice) shortened tumor latency and accelerated tumor growth, ultimately reducing overall survival. Tumors overproducing PTHrP also displayed increased expression of nuclear pSTAT5 and Elf5, increased expression of markers of secretory differentiation and milk constituents, and histologically resembled secretory carcinomas of the breast. Overexpression of PTHrP within cells isolated from tumors, but not PTHrP exogenously added to cell culture media, led to activation of STAT5 and milk protein gene expression. In addition, neither ablating the Type 1 PTH/PTHrP receptor (PTH1R) in epithelial cells nor treating Tet-PTHrP;PyMT mice with an anti-PTH1R antibody prevented secretory differentiation or altered tumor latency. These data suggest that PTHrP acts in a cell-autonomous, intracrine manner. Finally, expression of PTHrP in human breast cancers is associated with expression of genes involved in milk production and STAT5 signaling.

conclusionsOur study suggests that PTHrP promotes pathways leading to secretory differentiation and proliferation in both normal mammary epithelial cells and in breast tumor cells.

Indexed as

Breast NeoplasmsMammary Neoplasms, AnimalParathyroid Hormone-Related ProteinSTAT5 Transcription FactorAnimalsFemaleHumansLactationMammary Glands, AnimalMiceParathyroid Hormone-Related ProteinSTAT5 Transcription FactorBreast cancerLactationMilkParathyroid hormone-related proteinProliferationPTHLHPyMTSecretory carcinoma of the breast

Identifiers

PMID35440032
PMCPMC9020078
OpenAlexW4224311293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.